Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Inventiva (IVA) Stock Price & Analysis

IVA Stock Chart & Stats

€3.18-€0.17(-4.93%)
At close: 5:30 PM GMT+1
EUR 3EUR 3.5EUR 43 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
EUR 3.17 - EUR 3.34
52-Week Range
EUR 2.57 - EUR 6.20
Previous Close
EUR 3.35
Volume
253.81K
Average Volume (3M)
656.15K
Market Cap
EUR 760.35M
Enterprise Value
EUR 781.47M
Total Cash (Recent Filing)
EUR 166.13M
Total Debt (Recent Filing)
EUR 66.66M
Price to Earnings (P/E)
―
Beta
0.15
Next Earnings
Mar 31, 2027 (Est.)
EPS Estimate
-0.29
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Phase III Execution

Completing recruitment and final patient visits keeps Inventiva on a defined clinical timetable and reduces enrollment execution risk. The large, biopsy-confirmed cohort provides a meaningful validation event that could support regulatory progress and commercial planning over the next several quarters.

Clinical Efficacy Evidence

The phase II-B results provide a substantive efficacy foundation for lanifibranor before the pivotal readout. Consistent improvements across fibrosis, MASH resolution, and the composite endpoint strengthen the clinical rationale and support potential differentiation if Phase III confirms the effect.

Near-Term Funding Runway

Funding that extends through the expected Phase III readout and potential NDA filing gives Inventiva time to reach important value-creating milestones without an immediate financing requirement. This improves execution continuity, although later extension depends on additional conditions and financing outcomes.

Bears Say

Negative Equity And Leverage

Negative equity indicates that accumulated losses have overwhelmed the capital base, limiting financial flexibility and weakening the balance sheet ahead of major development decisions. Increased debt further raises leverage pressure and can constrain the company's ability to absorb setbacks or fund future programs.

Persistent Cash Burn And Losses

Persistent negative operating and free cash flow shows that development activity is consuming substantial cash rather than funding itself. Worsening 2025 outflows increase dependence on external capital and make the company's ability to sustain the pipeline sensitive to financing access and clinical progress.

Unapproved Lead Candidate

The core investment case remains dependent on an unapproved drug and a pending Phase III outcome, leaving regulatory and clinical risk unresolved. Until NATiV3 delivers supportive data, the projected filing and commercial launch are plans rather than established revenue drivers.

Inventiva News

IVA FAQ

What was Inventiva’s price range in the past 12 months?
Inventiva lowest stock price was €2.57 and its highest was €6.20 in the past 12 months.
What is Inventiva’s market cap?
Inventiva’s market cap is €760.35M.
When is Inventiva’s upcoming earnings report date?
Inventiva’s next earnings report is estimated for Mar 31, 2027 (not yet confirmed), which is in 149 days.
How were Inventiva’s earnings last quarter?
Inventiva released its earnings results on Sep 28, 2026. The company reported -€0.177 earnings per share for the quarter, beating the consensus estimate of -€0.332 by €0.155.
Is Inventiva overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Inventiva pay dividends?
Inventiva does not currently pay dividends.
What is Inventiva’s EPS estimate?
Inventiva’s EPS estimate is -0.29.
How many shares outstanding does Inventiva have?
Inventiva has 239,148,180 shares outstanding.
What happened to Inventiva’s price movement after its last earnings report?
Inventiva reported an EPS of -€0.177 in its last earnings report, beating expectations of -€0.332. Following the earnings report the stock price went up 3.866%.
Which hedge fund is a major shareholder of Inventiva?
Currently, no hedge funds are holding shares in FR:IVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology